Myocardial Solutions' mission is to transform the cardiac and cancer care continuum towards heart failure prevention and standardized patient management. Through MyoStrain, we are pursuing a new standard of care built on proactive diagnostics, personalized medicine, and value-based care.
Leveraging more than 400 publications in clinical research and development, Myocardial Solutions has created MyoStrain, a rapid, patient-centric solution to support physicians in the early assessment and individualized treatment of heart dysfunction for cardiac and cancer care.
MyoStrain's rapid and reliable software enables physicians to focus on early detection of cardiac dysfunction, treatment intervention, and mitigation of disease progression.
By helping physicians quantify subtle changes in heart function, MyoStrain helps physicians to individualize treatment pathways, preserve heart health and monitor patients long-term.
MyoStrain offers solutions that have the potential to impact and improve clinical and economic outcomes to the health care system across cardiac diseases and clinical specialties.
"MyoStrain is a paradigm shift in the way physicians identify patients at risk of heart failure. MyoStrain combines the power of high-speed MRI with novel cardiac information to give physicians a standardized, transformative approach to evaluate subtle changes in heart function for cardiac and cancer patients."
Myocardial Solutions' team is comprised of innovative leaders with extensive experience developing and delivering life-changing technologies to worldwide markets.
Chairman & Chief Executive Officer
John Funkhouser has extensive experience in healthcare as CEO of four cardiac life sciences companies including CoeurLabs, PharmaNetics, nContact and now, Myocardial Solutions. Before working in healthcare, Mr. Funkhouser worked in banking and venture capital at Chemical Bank Of New York, Wheat First Securities, Crestar Capital and Hillcrest Group. He is a graduate of Princeton University and the Darden School of Business at the University of Virginia.
Founder & Chief Science Officer
Nael Osman founded Myocardial Solutions after developing MyoStrain’s technology as a professor at Johns Hopkins University. As a known leader in cardiac MRI technology, Nael has pushed the frontiers of measuring regional function of the heart using MRI. Nael is an accomplished researcher and academician with a track record of academic publications (60+ scientific papers, 100+ conference presentations and abstracts), research contribution, teaching and life science innovation.
Chief Clinical Officer
Jim Whayne joined Myocardial Solutions to direct clinical initiatives. He has 25 years of medical device and entrepreneurial experience, having cofounded 3 device companies – nContact, Cayenne Medical and Converge Medical. Mr. Whayne holds a Master of Science in Biomedical Engineering from the University of Virginia and a Bachelor Degree in Biomedical and Electrical Engineering from Duke University. He is also an inventor on over 200 issued US patents.
Chief Medical Officer & Global Head of Medical Affairs
VP of Engineering and Operations
Sidney Fleischman has 25 years of experience in bringing medical devices from concept to commercialization. He has cofounded several successful medical device companies, including nContact, Cayenne Medical, and Converge Medical. He holds a BS in Mechanical Engineering from UC Santa Barbara and is an inventor of more than 100 issued patents in the medical device area.
VP of Finance
Denise McKenzie has extensive experience in finance and accounting with a variety of start-up companies, primarily in the healthcare industry. She has led diverse financing projects including IPOs, commercial bank financing, PIPEs, private placements, venture rounds, and acquisitions. McKenzie is a graduate of Virginia Commonwealth University with both a Bachelor’s and Master’s degree in finance with a concentration in accounting.
Myocardial Solutions' Software Development Team